TRAVASOL- leucine, phenylalanine, lysine hydrochloride, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, tyrosine, serine injection

Baxter Healthcare Corporation

----------

10% TRAVASOL (Amino Acid) Injection
Pharmacy Bulk Package
Not for Direct Infusion
in VIAFLEX Plastic Container

DESCRIPTION

10% TRAVASOL (Amino Acid) Injection is a sterile, nonpyrogenic hypertonic solution of essential and nonessential amino acids in a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25ºC/77ºF during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological test for plastic containers as well as by tissue culture toxicity studies.

Each 100 mL of 10% TRAVASOL (Amino Acid) Injection contains:

<table>
<thead>
<tr>
<th>Component</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amino acids</td>
<td>10 g</td>
</tr>
<tr>
<td>Total nitrogen</td>
<td>1.65 g</td>
</tr>
<tr>
<td>pH</td>
<td>6.0 (5.0 to 7.0)</td>
</tr>
</tbody>
</table>

(pH adjusted with glacial acetic acid.)

**Essential Amino Acids**

- Leucine - C₆H₁₃NO₂  730 mg
- Isoleucine - C₆H₁₃NO₂  600 mg
- Lysine (added as the hydrochloride salt) - C₆H₁₄N₂O₂  580 mg
- Valine - C₅H₁₁NO₂  580 mg
- Phenylalanine - C₉H₁₁NO₂  560 mg
- Histidine - C₆H₉N₃O₂  480 mg
- Threonine - C₄H₉NO₃  420 mg
- Methionine - C₅H₁₁NO₂S  400 mg
- Tryptophan - C₁₁H₁₂N₂O₂  180 mg

**Nonessential Amino Acids**

- Alanine - C₃H₇NO₂  2.07 g
- Arginine - C₆H₁₄N₄O₂  1.15 g
- Glycine - C₂H₅NO₂  1.03 g
- Proline - C₅H₉NO₂  680 mg
**Anion profiles per liter**

<table>
<thead>
<tr>
<th>Ion</th>
<th>mEq/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetate (1)</td>
<td>88</td>
</tr>
<tr>
<td>Chloride (2)</td>
<td>40</td>
</tr>
</tbody>
</table>

*Balanced by ions from amino acids.

(1) derived from pH adjustment with glacial acetic acid

(2) contributed by the lysine hydrochloride

**Osmolarity (Calc.)**

998 mOsmol/L

---

**CLINICAL PHARMACOLOGY**

10% TRAVASOL (Amino Acid) Injection administered via central vein will provide biologically utilisable source material for protein synthesis when used with concentrated calorie sources (such as hypertonic dextrose or fat emulsion), electrolytes, vitamins, and minerals. Administered peripherally after appropriate dilution or with minimal calorie supplementation (such as 5% dextrose), it enhances the conservation of body protein.

**INDICATIONS AND USAGE**

10% TRAVASOL (Amino Acid) Injection is indicated as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns.

**Central Vein Administration:**

Central vein infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis such as for hypercatabolic or depleted patients or those requiring long term parenteral nutrition.

**Peripheral Vein Administration:**

For patients in whom the central vein route is not indicated, amino acid solutions diluted with low dextrose concentrations may be infused by peripheral vein when supplemented with or without fat emulsion.

**Protein-Sparing:**

Dilute amino acid solutions for peripheral administration may be used in patients who exemplify no clinically significant protein malnutrition. The purpose of the solution is to replace protein losses which occur in relation to an intercurrent phenomenon which is known or suspected to be productive of a protein loss condition for a short or moderate period of time. Protein-sparing can be achieved by peripheral infusion of amino acid solutions with or without dextrose.

**CONTRAINDICATIONS**

Hypersensitivity to one or more amino acids

Severe liver disease or hepatic coma

Anuria

**WARNINGS**
This injection is for compounding only, not for direct infusion.

Caution should be exercised when admixing 10% TRAVASOL (Amino Acid) Injection. Studies have shown that admixtures of TRAVASOL (Amino Acid) Injection, 10% and 20% TRAVAMULSION Intravenous Fat Emulsion injection and high concentration dextrose injection (10 to 70%), from Baxter Healthcare Corporation, are stable over short periods of time. These solutions should be used promptly after admixing. Any storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours. Reference should be made to TRAVAMULSION injection and high concentration dextrose injection from Baxter Healthcare Corporation package inserts for detailed information on each component.

Proper administration of this injection requires knowledge of fluid and electrolyte balance and nutrition as well as clinical expertise in recognition and treatment of the complications which may occur.

Administration of amino acid solutions to a patient with hepatic insufficiency may result in serum amino acid imbalances, hyperammonemia, stupor and coma.

Hyperammonemia is of special significance in infants. This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured frequently in infants.

Conservative doses of this injection should be given to patients with known or suspected hepatic dysfunction. Should symptoms of hyperammonemia develop, administration should be discontinued and the patient's clinical status reevaluated.

Administration of amino acid solutions in the presence of impaired renal function presents special issues associated with retention of electrolytes.

This injection should not be administered simultaneously with blood through the same infusion set because of the possibility of pseudoagglutination.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 µg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Administration by central venous catheter should be used only by those familiar with this technique and its complications.

PRECAUTIONS

It is essential to provide adequate calories concurrently if parenterally administered amino acids are to be retained by the body and utilized for protein synthesis. Concentrated dextrose solutions are an effective source of such calories.

With the administration of 10% TRAVASOL (Amino Acid) Injection in combination with highly concentrated dextrose solutions, hyperglycemia, glycosuria and hyperosmolar syndrome may result. Blood and urine glucose should be monitored on a routine basis in patients receiving this therapy.

Sudden cessation in administration of a concentrated dextrose solution may result in insulin reaction due to continued endogenous insulin production. Parenteral nutrition mixtures should be withdrawn slowly. Electrolytes may be added to this injection as dictated by the patient's electrolyte profile.

The metabolizable acetate anion and amino acid profile in this injection were designed to minimize or prevent occurrences of hyperchloremic metabolic acidosis and hyperammonemia. However, the
physician should be aware of appropriate countermeasures if they become necessary.

Strongly hypertonic nutrient solutions should be administered through an indwelling intravenous catheter with the tip located in the superior vena cava.

Because of its antianabolic activity, concurrent administration of tetracycline may reduce the protein-sparing effects of infused amino acids.

Care should be taken to avoid excess fluid accumulation, particularly in patients with renal disease, pulmonary insufficiency and heart disease.

During protein-sparing therapy in the absence of supporting carbohydrate metabolism, an accumulation of ketone bodies in the blood often occurs. Correction of ketonemia usually can be accomplished by administering some carbohydrates.

Protein-sparing therapy is useful for periods up to 10 to 12 days. Patients requiring nutritional support thereafter should be placed on oral or parenteral regimens that employ adequate nonprotein calorie components.

Drug product contains no more than 25 µg/L of aluminum.

Laboratory Tests

Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring during administration.

Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide combining power or content, serum osmolarities, blood cultures and blood ammonia levels.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Studies with 10% TRAVASOL (Amino Acid) Injection have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Pregnancy:

Teratogenic Effects

Pregnancy Category C.

Animal reproduction studies have not been conducted with 10% TRAVASOL (Amino Acid) Injection. It is also not known whether 10% TRAVASOL (Amino Acid) Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 10% TRAVASOL (Amino Acid) Injection should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

Caution should be exercised when 10% TRAVASOL (Amino Acid) Injection is administered to a nursing woman.

Pediatric Use:

Safety and effectiveness of 10% TRAVASOL (Amino Acid) Injection in pediatric patients have not been established by adequate and well-controlled studies. However, the use of amino acid injections in pediatric patients as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance is referenced in the medical literature. See Dosage and Administration.

SPECIAL PRECAUTIONS

Administration of amino acid solutions and other nutrients via central or peripheral venous catheter may
be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure. This includes attention to solution preparation, administration and patient monitoring. **It is essential that a carefully prepared protocol, based on current medical practices, be followed, preferably by an experienced team.**

Although a detailed discussion of the complications is beyond the scope of this insert, the following summary lists those based on current literature:

**Technical:**

The placement of a central venous catheter should be regarded as a surgical procedure. The physician should be fully acquainted with various techniques of catheter insertion as well as recognition and treatment of complications. For details of techniques and placement sites consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arterio-venous fistula, phlebitis, thrombosis, cardiac arrhythmia and catheter embolus.

**Septic:**

The constant risk of sepsis is present during administration of parenteral nutrition solutions. Since contaminated solutions and infusion catheters are potential sources of infection, it is imperative that the preparation of the solution and the placement and care of catheters be accomplished under controlled aseptic conditions. If fever develops, the solution, its delivery system and the site of the indwelling catheter should be changed.

Solutions ideally should be prepared in the hospital pharmacy under a laminar flow hood. The key factor in their preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.

**Metabolic:**

The following metabolic complications have been reported: metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia and glycosuria, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, hypo and hyper vitaminosis, electrolyte imbalances and hyperammonemia. Frequent clinical evaluation and laboratory determinations are necessary, especially during the first few days of therapy, to prevent or minimize these complications.

**ADVERSE REACTIONS**

See Warnings and Special Precautions.

Infusion of any hypertonic solution can result in local inflammatory reactions. Policies and procedures should be established for the recognition and management of such reactions.

**OVERDOSAGE**

See Contraindications and Warnings

**DOSAGE AND ADMINISTRATION**

If a patient is unable to take enteral nourishment for a prolonged period of time, institution of total parenteral nutrition (TPN) with exogenous calories should be considered.

The total daily dose of 10% TRAVASOL (Amino Acid) Injection depends on the patient’s metabolic requirement and clinical response. The determination of nitrogen balance and accurate daily body weights, corrected for fluid balance, are probably the best means of assessing individual nitrogen
Recommended Dietary Allowances\(^*\) of protein range from approximately 0.75 g/kg of body weight for adults to 1.68 g/kg for infants. It must be recognized, however, that protein as well as caloric requirements in traumatized or malnourished patients may be increased substantially. Daily amino acid doses of approximately 1.0 to 1.5 g/kg of body weight for adults with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance.

For the initial treatment of trauma or protein calorie malnutrition, higher doses of protein with corresponding quantities of carbohydrate will be necessary to promote adequate patient response to therapy. The severity of the illness being treated is the primary consideration in determining proper dose level. Such higher doses, especially in infants, must be accompanied by more frequent laboratory evaluation.

For protein-sparing in well-nourished patients not receiving significant additional calories, amino acid dosages of 1.0 to 1.7 g/kg/day reduce nitrogen losses and spare body protein. If daily increases in BUN in the range of 10 to 15 mg% for more than three days should occur, then protein-sparing therapy should be discontinued and a regimen with full nonprotein calorie substrates should be adopted.

Care should be exercised to insure the maintenance of proper levels of serum potassium. Quantities of 60 to 180 mEq of potassium per day have been used with adequate clinical effect. It may be necessary to add quantities of this electrolyte to this injection, depending primarily on the amount of carbohydrate administered to and metabolized by the patient.

This injection provides a concentrated source of amino acids to meet the protein requirements of patients that are fluid restricted (e.g., renal failure). Acceptable total daily administration volumes are dependent upon the fluid balance requirements of the patient. Extreme care should be given to prevent fluctuations of blood osmolarity and serum electrolyte concentrations. Frequent and careful monitoring is mandatory when fluid restricted patients are receiving intravenous nutrition.

Patients receiving this injection should be monitored (carefully) and their electrolyte requirements individualized.

Total daily fluid requirements can be met beyond the volume of amino acid solutions by supplementing with noncarbohydrate or carbohydrate-containing electrolyte solutions.

*Food and Nutrition Board National Academy of Sciences – National Research Council (Revised 1989)

Maintenance vitamins, additional electrolytes and trace elements should be administered as required.

Fat emulsion coadministration should be considered when prolonged parenteral nutrition (more than 5 days) is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat free total parenteral nutrition.

**Pediatric Use:**

Use of 10% TRAVASOL (Amino Acid) Injection in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L).

**Central Vein Administration:**

Hypertonic mixtures of amino acids and dextrose may be administered safely by continuous infusion through a central vein catheter with the tip located in the vena cava. In addition to meeting nitrogen needs, the administration rate is governed, especially during the first few days of therapy, by the patient's tolerance to dextrose. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of urine and blood sugar levels.
In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria.

Parenteral nutrition may be started with infusates containing lower concentrations of dextrose; dextrose content may be gradually increased to estimated caloric needs as the patient's glucose tolerance increases.

Sudden cessation in administration of concentrated dextrose solution may result in insulin reaction due to continued endogenous insulin production. Such solutions should be withdrawn slowly.

**Peripheral Vein Administration:**

For patients requiring parenteral nutrition in whom the central vein route is not indicated, this injection can be mixed with low concentration dextrose solutions and administered by peripheral vein in conjunction with or without fat emulsions. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).

Intravenous fat emulsions provide approximately 1.1 kcal/mL (10%) or 2.0 kcal/mL (20%) and may be administered along with amino acid-dextrose solutions by means of a short Y-connector near the infusion site to supplement caloric intake. Fat, however, should not be the sole caloric intake since studies have indicated that glucose is more nitrogen sparing in the stressed patient.

**Protein-Sparing:**

For well-nourished patients who require short-term parenteral support, 10% TRAVASOL (Amino Acid) Injection can be administered peripherally with or without carbohydrate calories. Such infusates can be prepared by dilution of this injection with Sterile Water for Injection or 5% Dextrose Injection to prepare isotonic or slightly hypertonic solutions which may be administered by peripheral vein.

Depending upon the clinical condition of the patient, approximately 3 liters of solution may be administered per 24 hour period. When used postoperatively, the therapy should begin with 1000 mL on the first postoperative day. Thereafter, the dose may be increased to 3000 mL per day.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible.

Do not administer unless solution is clear and seal is intact.

A slight yellow color does not alter the quality and efficacy of the product.

10% TRAVASOL (Amino Acid) Injection in the Pharmacy Bulk Package is intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of 10% TRAVASOL (Amino Acid) Injection.

Any storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours.

**Directions for use of VIAFLEX plastic Pharmacy Bulk Package container**

**To Open**

Tear overpouch down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will
diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

For compounding only, not for direct infusion.

Preparation for Admixing
1. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area).
2. Suspend container from eyelet support.
3. Remove plastic protector from outlet port at bottom of container.
4. Attach solution transfer set. Refer to complete directions accompanying set. Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.
5. VIAFLEX containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry.
6. Once container closure has been penetrated, withdrawal of contents should be completed without delay. After initial entry, maintain contents at room temperature (25ºC/77ºF) and dispense within 4 hours.

HOW SUPPLIED
10% TRAVASOL (Amino Acid) Injection is available in VIAFLEX plastic Pharmacy Bulk Package containers as follows below.

<table>
<thead>
<tr>
<th>Container Code</th>
<th>Volume</th>
<th>NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1B6623</td>
<td>500 mL</td>
<td>0338-0644-03</td>
</tr>
<tr>
<td>1B6624</td>
<td>1000 mL</td>
<td>0338-0644-04</td>
</tr>
<tr>
<td>1B6626</td>
<td>2000 mL</td>
<td>0338-0644-06</td>
</tr>
</tbody>
</table>

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25ºC/77ºF).

Do not remove container from overpouch until ready to use.

Do not use if overpouch has been previously opened or damaged.

Baxter Healthcare Corporation
Deerfield, IL 60015 USA

Printed in USA
07-19-73-000
Rev. April 2014

Baxter, Travasol, Viaflex, and PL 146 are trademarks of Baxter International Inc.

Distributed in Canada by
Baxter Corporation
Mississauga, ON L5N 0C2

PACKAGEING LABELING - PRINCIPAL DISPLAY PANEL
10% TRAVASOL (Amino Acid) Injection

Pharmacy Bulk Package Not For Direct Infusion

Rx Only

EACH 100 mL CONTAINS ESSENTIAL AMINO ACIDS LEUCINE 730 mg ISOLEUCINE 600 mg LYSINE (ADDED AS THE HYDROCHLORIDE SALT) 580 mg VALINE 580 mg PHENYLALANINE 560 mg HISTIDINE 480 mg THREONINE 420 mg METHIONINE 400 mg TRYPTOPHAN 180 mg NONESSENTIAL AMINO ACIDS ALANINE 2.07 g ARGININE 1.15 g GLYCINE 1.03 g PROLINE 680 mg SERINE 500 mg TYROSINE 40 mg pH ADJUSTED WITH GLACIAL ACETIC ACID pH 6.0 (5.0 TO 7.0)
mEq/L*: ACETATE - 88 CHLORIDE - 40
*BALANCED BY IONS FROM AMINO ACIDS
HYPERTONIC OSMOLARITY 998 mOsmol/L (CALC)
STERILE NONPYROGENIC
CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM
ADDITIVES MAY BE INCOMPATIBLE WITH THE FLUID WITHDRAWN FROM THIS CONTAINER CONSULT WITH PHARMACIST IF AVAILABLE WHEN COMPOUNDING ADMIXTURES USE ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE

DOSAGE ADMIX FOR INTRAVENOUS ADMINISTRATION AS DIRECTED BY A PHYSICIAN SEE ACCOMPANYING DIRECTIONS FOR USE

ONCE CONTAINER CLOSURE HAS BEEN PENETRATED WITHDRAWAL OF CONTENTS SHOULD BE COMPLETED WITHOUT DELAY AFFIX ACCOMPANYING LABEL FOR DATE AND TIME OF ENTRY DISPENSE CONTENTS WITHIN 4 HOURS AFTER INITIAL ENTRY

CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR AND SEAL IS INTACT
A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY AND EFFICACY OF THE PRODUCT

VIAFLEX CONTAINER

Baxter

BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
MISSISSAUGA ON L5N 0C2
BAXTER TRAVASOL VIAFLEX AND PL 146 ARE TRADEMARKS OF BAXTER INTERNATIONAL INC

Container Label
LOT EXP
1B6624 1000 mL
NDC 0338-0644-04 DIN 00872296

10% TRAVASOL
10%
(Amino Acid)
Injection

Pharmacy Bulk Package
Not For Direct Infusion

Rx Only

EACH 100mL CONTAINS ESSENTIAL AMINO ACIDS LEUCINE 730 mg
ISOLEUCINE 600 mg LYSINE (ADDED AS THE HYDROCHLORIDE SALT) 580 mg VALINE 580
mg PHENYLALANINE 560 mg HISTIDINE 480 mg
THREONINE 420 mg METHIONINE 400 mg TRYPTOPHAN 180 mg

NONESSENTIAL AMINO ACIDS ALANINE 2.07 g ARGinine 1.15 g
GLYCINE 1.03 g PROLINE 680 mg SERINE 500 mg TYROSINE 40 mg
pH ADJUSTED WITH GLACIAL ACETIC ACID pH 6.0 (5.0 TO 7.0)

mEq/L* ACETATE - 88 CHLORIDE - 40
*BALANCED BY IONS FROM AMINO ACIDS
HYPERTONIC OSMOLARITY 998 mOsmo/L (CALC)
STERILE NONPYROGENIC

CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM
ADDITIVES MAY BE INCOMPATIBLE WITH THE FLUID WITHDRAWN
FROM THIS CONTAINER CONSULT WITH PHARMACIST IF AVAILABLE
WHEN COMPOUNDING ADMIXTURES USE ASEPTIC TECHNIQUE
MIX THOROUGHLY DO NOT STORE

DOSAGE ADMIX FOR INTRAVENOUS ADMINISTRATION AS DIRECTED
BY A PHYSICIAN SEE ACCOMPANYING DIRECTIONS FOR USE

ONCE CONTAINER CLOSURE HAS BEEN PENETRATED
WITHDRAWAL OF CONTENTS SHOULD BE COMPLETED
WITHOUT DELAY AFFIX ACCOMPANYING LABEL FOR DATE
AND TIME OF ENTRY DISPENSE CONTENTS WITHIN 4 HOURS
AFTER INITIAL ENTRY

CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR AND
SEAL IS INTACT

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY AND
EFFICACY OF THE PRODUCT

VIAFLEX CONTAINER

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN THE USA
PL 146 PLASTIC
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
Lot: xx
QTY: 24-500mL
Exp: x x
Code: 1B6623
NDC: 0338-0644-03
10% Travasol (Amino Acid) INJ Viaflex Container

BAXTER TRAVASOL VIAFLEX
AND PL 146 ARE TRADEMARKS
OF BAXTER INTERNATIONAL INC
TRAVASOL
leucine, phenylalanine, lysine hydrochloride, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, tyrosine, serine injection

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:0338-0644</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRAVENOUS</td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEUCINE (UNII: GMW67QNF9C)</td>
<td>LEUCINE</td>
<td>730 mg in 100 mL</td>
</tr>
<tr>
<td>PHENYLALANINE (UNII: 47E5017Y3R)</td>
<td>PHENYLALANINE</td>
<td>560 mg in 100 mL</td>
</tr>
<tr>
<td>LYSINE HYDROCHLORIDE (UNII: JNJZ4F929H)</td>
<td>LYSINE</td>
<td>580 mg in 100 mL</td>
</tr>
<tr>
<td>METHIONINE (UNII: AE28F7PNPL)</td>
<td>METHIONINE</td>
<td>400 mg in 100 mL</td>
</tr>
<tr>
<td>ISOLEUCINE (UNII: 04Y7S90D77)</td>
<td>ISOLEUCINE</td>
<td>600 mg in 100 mL</td>
</tr>
<tr>
<td>VALINE (UNII: HG18B9YRS7)</td>
<td>VALINE</td>
<td>580 mg in 100 mL</td>
</tr>
<tr>
<td>HISTIDINE (UNII: 4QD397987E)</td>
<td>HISTIDINE</td>
<td>480 mg in 100 mL</td>
</tr>
<tr>
<td>THREONINE (UNII: 2ZD004190S)</td>
<td>THREONINE</td>
<td>420 mg in 100 mL</td>
</tr>
<tr>
<td>TRYPTOPHAN (UNII: 8DUHI1NBX)</td>
<td>TRYPTOPHAN</td>
<td>180 mg in 100 mL</td>
</tr>
<tr>
<td>ALANINE (UNII: OF5P57N2XX)</td>
<td>ALANINE</td>
<td>2.07 g in 100 mL</td>
</tr>
<tr>
<td>GLYCINE (UNII: TE7660XO1C)</td>
<td>GLYCINE</td>
<td>1.03 g in 100 mL</td>
</tr>
<tr>
<td>ARGinine (UNII: 94ZLA3W45F)</td>
<td>ARGinine</td>
<td>1.15 g in 100 mL</td>
</tr>
<tr>
<td>PROLINE (UNII: 9DQLQ4CI6V)</td>
<td>PROLINE</td>
<td>680 mg in 100 mL</td>
</tr>
<tr>
<td>TYROSINE (UNII: 42HK56048U)</td>
<td>TYROSINE</td>
<td>40 mg in 100 mL</td>
</tr>
<tr>
<td>SERINE (UNII: 452VLY9402)</td>
<td>SERINE</td>
<td>500 mg in 100 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID (UNII: Q40Q9N063P)</td>
<td></td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KOOR)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0338-0644-03</td>
<td>500 mL in 1 BAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0338-0644-04</td>
<td>1000 mL in 1 BAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0338-0644-06</td>
<td>2000 mL in 1 BAG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA018931</td>
<td>08/23/1984</td>
<td></td>
</tr>
</tbody>
</table>
**Labeler** - Baxter Healthcare Corporation (005083209)

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baxter Healthcare Corporation</td>
<td>189326168</td>
<td></td>
<td>ANALYSIS(0338-0644), MANUFACTURE(0338-0644), LABEL(0338-0644), PACK(0338-0644), STERILIZE(0338-0644)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baxter Healthcare Corporation</td>
<td></td>
<td>078539510</td>
<td>ANALYSIS(0338-0644)</td>
</tr>
</tbody>
</table>

Revised: 4/2014

Baxter Healthcare Corporation